EzekowitzJO’MearaEMcDonaldM, et al. 2017 Comprehensive update of the Canadian Cardiovascular Society guidelines for the management of heart failure. Can J Cardiol2017;33:1342-433.
3.
GunadiSUpfieldSPhamNDYeaJSchmiedebergMBStahmerGD. Development of a collaborative transitions-of-care program for heart failure patients. Am J Health Syst Pharm2015;72:1147-52.
4.
MurrayMDYoungJHokeS, et al. Pharmacist intervention to improve medication adherence in heart failure: a randomized trial. Ann Intern Med2007;146:714-25.
5.
DavisEMPackardKAJackeviciusCA. The pharmacist role in predicting and improving medication adherence in heart failure patients. J Manag Care Pharm2014;20(7):741-55.
6.
StewartSPearsonSHorowitzJD. Effects of a home-based intervention among patients with congestive heart failure discharged from acute hospital care. Arch Intern Med1998;158:1067-72.
7.
EgginkRNLenderinkAWWiddershovenJWvan den BemtPM. The effect of a clinical pharmacist discharge service on medication discrepancies in patients with heart failure. Pharm World Sci2010;32:759-66.
8.
MurrayMDYoungJHokeS, et al. Pharmacist intervention to improve medication adherence in heart failure: a randomized trial. Ann Intern Med2007;146:714-25.
9.
Lopez CabezasCSalvadorCQuadradaD, et al. Randomized clinical trial of a postdischarge pharmaceutical care program vs regular follow-up in patients with heart failure. Farm Hosp2006;30:328-42.
10.
JackeviciusCAde LeonNKLuLChangDSWarnerALModyFV. Impact of a multidisciplinary heart failure post-hospitalization program on heart failure readmission rates. Ann Pharmacother2015;49(11):1189-96.
11.
VarmaSMcElnayJCHughesCMPassmoreAPVarmaM. Pharmaceutical care of patients with congestive heart failure: interventions and outcomes. Pharmacotherapy1999;19(7):861-9.
12.
RougheadEEBarrattJDRamsayE, et al. The effectiveness of collaborative medicine reviews in delaying time to next hospitalization for patients with heart failure in the practice setting: results of a cohort study. Circ Heart Fail2009;2(5):424-8.
13.
CoonsJCFeraT. Multidisciplinary team for enhancing care for patients with acute myocardial infarction or heart failure. Am J Health Syst Pharm2007;64:1274-8.
14.
MurrayMDRitcheyMEWuJTuW. Effect of a pharmacist on adverse drug events and medication errors in outpatients with cardiovascular disease. Arch Intern Med2009;169:757-63.
15.
HaynesKTOberneACawthonCKripalaniS. Pharmacists’ recommendations to improve care transitions. Ann Pharmacother2012;46:1152-9.
16.
EgginkRNLenderinkAWWiddershovenJWvanden BemtPM. The effect of a clinical pharmacist discharge service on medication discrepancies in patients with heart failure. Pharm World Sci2010;32:759-66.
17.
MartinezASSaefJPaszczukABhatt-ChuganiH. Implementation of a pharmacist-managed heart failure medication titration clinic. Am J Health Syst Pharm2013;70:1070-6.
18.
GattisWAHasselbladVWhellanDJO’ConnorCM. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) Study. Arch Intern Med1999;159:1939-45.
19.
JainAMillsPNunnLM, et al. Success of a multidisciplinary heart failure clinic for initiation and up-titration of key therapeutic agents. Eur J Heart Fail2005;7(3):405-10.
20.
HaleGMHassanSLHummelSLLewisCRatzDBrennerM. Impact of a pharmacist-managed heart failure postdischarge (bridge) clinic for veterans. Ann Pharmacother2017;51(7):555-62.
21.
ZannadFMcMurrayJJKrumH; et al. EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med2011;364(1):11-21.
22.
PittBZannadFRemmeWJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med1999;341(10):709-17.
23.
McMurrayJJPackerMDesaiAS; et al. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med2014;371(11):993-1004.
24.
SwedbergKKomajdaMBöhmM; et al. SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet2010;376(9744):875-85.
25.
LakhdarRAl-MallahMHLanfearDE. Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials. J Card Fail2008;14:181-8.
26.
VermaACairnsJAMitchellLB; et al. CCS Atrial Fibrillation Guidelines Committee. 2014 Focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. Can J Cardiol2014;30(10):1114-30.
27.
ZinmanBWannerCLachinJM; et al. EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med2015;373(22):2117-28.
28.
NealBPerkovicVMahaffeyKW; et al. CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med2017;377(7):644-57.
29.
SciricaBMBhattDLBraunwaldE; et al. SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med2013;369(14):1317-26.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
